Wenzhou Kangning Hospital Full Year 2024 Earnings: EPS: CN¥0.88 (vs CN¥1.15 in FY 2023)

Simply Wall St

April 30, 2025

Wenzhou Kangning Hospital (HKG:2120) Full Year 2024 Results

Key Financial Results

Revenue: CN¥1.65b (up 3.6% from FY 2023).
Net income: CN¥65.6m (down 24% from FY 2023).
Profit margin: 4.0% (down from 5.4% in FY 2023).
EPS: CN¥0.88 (down from CN¥1.15 in FY 2023).

Our free stock report includes 4 warning signs investors should be aware of before investing in Wenzhou Kangning Hospital. Read for free now.

revenue-and-expenses-breakdown — SEHK:2120 Revenue and Expenses Breakdown April 30th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Healthcare Facilities & Services contributing CN¥1.65b. Notably, cost of sales worth CN¥1.23b amounted to 74% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CN¥235.5m (65% of total expenses). Explore how 2120's revenue and expenses shape its earnings.

Wenzhou Kangning Hospital's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with Wenzhou Kangning Hospital (including 1 which is a bit concerning).

If you're looking to trade Wenzhou Kangning Hospital, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Wenzhou Kangning Hospital might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.